{"filings":[{"id":482797,"accession_number":"0001801170-26-000128","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2026-05-18T12:32:42+00:00","items":["7.01","9.01"],"status":"ready","headline":"Clover Health publishes supplemental Q&A for Q1 2026; no specific financial details in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished a supplemental Q&A document responding to shareholder questions about Q1 2026 earnings.","No numerical data, guidance changes, or material updates are present in the provided exhibit excerpt.","CEO Andrew Toy reiterated commitment to transparency and shareholder engagement.","Document is available on the investor relations section of Clover Health's website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95550,"accession_number":"0001801170-26-000114","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clover Health posts Q1 GAAP net income of $27M; revenue up 62% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $27.3M vs $(1.3)M in Q1 2025; first positive GAAP net income quarter.","Total revenue $749M (+62% YoY); Medicare Advantage membership 155,773 (+51% YoY).","Consolidated Gross Profit $159.5M (+47% YoY); Adjusted EBITDA $40.3M (+56% YoY).","Full-year 2026 guidance: revenue $2.81B-$2.92B, GAAP net income $0M-$20M.","Expects to meet or exceed full-year outlook with first full year of GAAP net income profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":749189000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95549,"accession_number":"0001801170-26-000080","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Clover Health CFO Peter Kuipers steps down; Clay Thornton named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter Kuipers resigns as CFO effective March 30, 2026; will advise through April 24, 2026.","Clay Thornton, current CFO of Clover Insurance, appointed Interim CFO and principal financial officer.","Joe Oldakowski, VP of Finance and Controller, appointed principal accounting officer.","Departure not due to any disagreement on operations, policies, or practices.","Company reiterates full-year 2026 financial guidance previously issued on February 26, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108701,"accession_number":"0001801170-26-000069","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Clover Health publishes supplemental Q&A re Q4 2025 earnings","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01; responses to frequently asked questions from shareholders.","Document is furnished as Exhibit 99.1; available on investor relations page.","No new financial results or guidance disclosed in the 8-K filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108698,"accession_number":"0001801170-26-000071","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K/A","filed_at":"2026-03-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Clover Health publishes supplemental shareholder Q&A; no new financial data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed 8-K/A on March 6, 2026 furnishing a supplemental Q&A document related to Q4 2025 earnings.","Document contains selected responses to shareholder questions but includes no specific financial or operational metrics.","CEO Andrew Toy reaffirms commitment to shareholder transparency in the accompanying letter.","Q&A is also available on the investor relations page of Clover Health's website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108700,"accession_number":"0001801170-26-000050","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clover Health Reports FY2025 Revenue Up 40% to $1.9B, Guides to First GAAP Net Income Profitability in FY2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 total revenues of $1.9 billion, up 40% year-over-year; GAAP net loss of $86 million.","Adjusted EBITDA of $22 million for 2025; Medicare Advantage membership grew 38% to 113,803.","Full year 2026 guidance: revenues $2.81B-$2.92B, GAAP net income $0M-$20M, Adjusted EBITDA $50M-$70M.","Expects first full year of GAAP Net Income profitability in 2026 driven by improving cohort economics and Clover Assistant.","2026 average Medicare Advantage membership guided to 154,000-158,000, representing 46% growth at midpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1924308000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108699,"accession_number":"0001801170-26-000020","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Clover Health reports 53% MA membership growth to 153k; expects first full-year GAAP net income profitability in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Medicare Advantage membership grew 53% YoY to ~153,000 as of Jan 1, 2026, driven by disciplined core-market growth.","Expects first-ever full-year GAAP net income profitability in 2026, citing improved cohort economics and SG&A leverage.","Over 97% of members in flagship PPO plan ranked #1 nationally on core HEDIS quality measures for 2nd consecutive year.","Over 95% returning member retention; favorable 2026 CMS rate update and 4.0 Stars rating for PPO plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125148,"accession_number":"0001801170-25-000284","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Clover Health discloses Counterpart Assistant performance update for external payors","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Counterpart Health subsidiary released performance outcomes and clinician adoption data for Counterpart Assistant technology.","Counterpart Assistant is a SaaS and tech-enabled solution for Medicare-eligible populations outside Clover Health.","No specific quantitative results or adoption metrics were included in the furnished disclosure.","Disclosure made under Item 7.01 as Regulation FD; not incorporated by reference into SEC filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125147,"accession_number":"0001801170-25-000279","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Clover Health publishes supplemental Q&A on Q3 2025 earnings; no new financial figures disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Regulation FD on Nov 12, 2025; document contains written responses to shareholder questions.","Q&A covers strategic direction and topics from Q3 2025 earnings call but provides no additional financial metrics.","CEO Andrew Toy emphasizes commitment to transparency and two-way shareholder communication.","No guidance changes, operational updates, or material non-public information included in the exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125146,"accession_number":"0001801170-25-000269","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clover Health Q3 revenue up 50% YoY to $497M, but cuts FY25 adjusted EBITDA guidance to $15M-$30M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP net loss $24.4M; revenue $496.7M vs $331M YoY; membership 109,226 (+35% YoY).","Adjusted EBITDA Q3 $2.1M; YTD $45M; FY guidance cut to $15M-$30M from prior $50M-$70M.","Insurance BER Q3 93.5%; full-year BER guidance raised to 90%-91% from 88.5%-89.5%.","Revised FY25 insurance revenue guidance up to $1.850B-$1.880B; midpoint +39% YoY.","Management cites new member mix and elevated utilization; sees 2026 tailwinds from 4-star payment and CMS rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1436601000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125145,"accession_number":"0001801170-25-000261","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Chelsea Clinton steps down from Clover Health Board effective Oct 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Clinton notified the Company on October 31, 2025; departure is immediate and not due to any disagreement.","She served over eight years, guiding Clover from private to public with membership growth from 30,000 to 100,000+.","Clinton was the longest-serving director and sat on Talent/Compensation and Nominating/Governance committees.","Board authorized number remains nine directors, with two vacant seats after departure; vacancy to be filled asap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125144,"accession_number":"0001801170-25-000253","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Clover Health's 2026 MA Star Ratings: PPO 3.5 Stars, HMO 4.0 Stars; Company confident in offsetting impact","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS awarded Clover's PPO plans 3.5 Stars and HMO plan 4.0 Stars for 2026 ratings, affecting payment year 2027.","CEO Andrew Toy states the Star rating does not dominate results due to Clover Assistant's AI-driven care improvements and platform momentum.","H1 2025 results: revenue up 34% YoY, membership up 32% YoY, sustained Adjusted EBITDA profitability.","Clover's PPO plans achieved HEDIS clinical quality score of 4.72, attributed to Clover Assistant platform.","Company actively engaging with CMS, believes Star methodology overweighs non-outcomes measures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141855,"accession_number":"0001801170-25-000217","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Executive chairman's Q&A highlights Clover's PPO success and AI edge","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Vivek Garipalli answers two shareholder questions on PPO model viability and AI in healthcare.","Clover claims its PPO model succeeds by building Clover Assistant to empower clinicians, not restrict access.","Company states AI is core to Clover Assistant, used to improve care rather than deny it, unlike competitors.","Garipalli views long-term competition as healthtech/AI-native startups, not traditional MA incumbents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141854,"accession_number":"0001801170-25-000196","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clover Health Q2 revenue $478M (+34% YoY), membership up 32%, GAAP net loss $11M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 total revenues $477.6M, up 34% YoY; insurance revenue $469.8M (+34.3%).","Medicare Advantage membership 106,323 (+32% YoY); avg membership 105,494 (+31.8%).","GAAP net loss from cont ops $10.6M; Adjusted net income $16.7M; Adjusted EBITDA $17.1M.","FY2025 guidance: membership raised to 104K-108K; Adj SG&A improved to $335M-$345M; Insurance BER guided to 88.5%-89.5% (from 87%-88%).","CEO highlights AI-driven clinical recommendations; published COPD whitepaper showing 15% fewer hospitalizations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":939951000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159793,"accession_number":"0001801170-25-000154","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Clover Health stockholders elect directors, approve pay, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Anna U. Loengard and William G. Robinson, Jr. elected as Class I directors for term expiring 2028.","Non-binding say-on-pay proposal for 2024 executive compensation approved with over 988 million votes in favor.","Ratification of Ernst & Young LLP as independent auditor for FY2025 received over 1.15 billion votes in favor.","All proposals passed with substantial majority; broker non-votes on first two items totaled ~162 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159792,"accession_number":"0001801170-25-000141","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Clover Health publishes shareholder Q&A ahead of Q1 2025 earnings; no financial data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Shareholder Q&A published on May 14, 2025 covering 10 frequently asked questions.","CEO Andrew Toy states the Q&A is part of effort to increase transparency and engagement.","No specific financial results, guidance changes, or material operational metrics are disclosed.","Company plans to hold similar Q&A sessions before future earnings announcements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159791,"accession_number":"0001801170-25-000127","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clover Health Q1 beat: revenue $462M (+33%), Adj EBITDA $26M (+279%); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $462M, up 33% YoY; GAAP net loss improved to $1M from $19M loss a year ago.","Adjusted EBITDA $26M, up 279% YoY; Adjusted Net income $25M, up 322% YoY.","Medicare Advantage membership 103,418, up 30% YoY; Insurance BER 86.1%.","Full-year 2025 Adj EBITDA guidance raised to $50M-$70M from $45M-$70M; revenue outlook unchanged.","CEO cites Clover Assistant's CHF whitepaper showing 18% lower all-cause hospitalizations."],"consensus_eps_estimate":0.0306,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":462331000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159790,"accession_number":"0001801170-25-000088","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Clover Health board member Lee Shapiro to not stand for re-election; Tran to chair committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lee Shapiro will not stand for re-election due to American Heart Association chairmanship; departure effective June 10, 2025.","Thomas Tran appointed Chairman of Audit Committee and Nominating & Corporate Governance Committee effective June 10.","No disagreement with company operations; Shapiro will finish his term through the annual meeting.","Board size unchanged at nine; vacancy will be filled as soon as practicable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178163,"accession_number":"0001801170-25-000049","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clover Health FY24 adjusted EBITDA $70M, net loss improves $164M; 2025 revenue guidance $1.8-1.875B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 GAAP net loss from continuing ops narrowed to $46M from $210M in 2023 (improvement of $164M).","Full year 2024 Adjusted EBITDA was $70M, reversing a $42M loss in 2023; Q4 Adj. EBITDA $7.8M vs -$16.7M.","Insurance revenue $1.344B for 2024 (+8.8% YoY); Insurance BER improved to 81.2% from 86.5%.","For 2025, guides insurance revenue $1.8-$1.875B (37% growth) and Adjusted EBITDA $45M-$70M.","Average Medicare Advantage membership expected 103k-107k in 2025 (~30% growth YoY at midpoint)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1371131000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178162,"accession_number":"0001801170-25-000029","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Clover Health reports 27% MA membership growth, surpasses 100,000 members after AEP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Medicare Advantage membership grew 27% YoY to over 100,000 as of January 1, 2025.","Approximately 95% of members are enrolled in Clover's flagship 4-Star PPO plan.","4-Star rating positions Clover for an anticipated 5% benchmark increase in PY26.","CEO Andrew Toy to present at 43rd Annual J.P. Morgan Healthcare Conference on Jan 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194826,"accession_number":"0001801170-24-000231","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clover Health Q3 net loss narrows to $8.8M; raises FY 2024 Adj. EBITDA guidance to $55-65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss from continuing ops improved to $8.8M from $33.6M YoY; Adjusted EBITDA rose to $19.3M from $2.7M.","Total revenue $331M (+8.2% YoY); insurance revenue $322.6M (+7.1% YoY); Insurance MCR improved 50 bps to 78.0%.","Year-to-date GAAP net loss improved $117.4M and Adjusted EBITDA improved $87.2M vs 2023.","New FY 2024 guidance: Insurance BER 81-82%, Adj. EBITDA $55-65M (midpoint raised $5M), Adj. SG&A $290-295M.","Flagship PPO plan achieved 4.0 Stars for payment year 2026; management plans to invest in membership growth in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1034168000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194825,"accession_number":"0001801170-24-000220","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Clover Health pays $250,000 to settle shareholder lawsuit fee claim","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Plaintiff challenged board nomination bylaw as preclusive; company amended bylaw to moot action.","To avoid further litigation, Clover agreed to pay $250,000 to plaintiff's counsel for fees and expenses.","Case was dismissed voluntarily after bylaw amendment; court retained jurisdiction only for fee application."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194824,"accession_number":"0001801170-24-000204","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Clover Health's PPO Medicare Advantage Plans Earn 4 Star Rating from CMS for 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS raised Clover Health PPO Medicare Advantage plans to 4 Stars for 2025, affecting payment year 2026.","Company expects a 5% quality bonus increase in benchmark rates in payment year 2026 due to the 4.0 Star rating.","Over 95% of Clover's MA membership is served through its PPO plans.","Clover's HMO plan also improved to 3.5 Stars; HEDIS score was 4.94 out of 5 Stars.","Higher Star rating allows Clover to reinvest in competitive benefits and fuel membership growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211119,"accession_number":"0001801170-24-000195","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SEC concludes Clover Health investigation, will not recommend enforcement action","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SEC staff notified Clover Health on Sept 26, 2024 that the investigation begun in Feb 2021 is closed.","Based on information as of the notice date, staff does not intend to recommend SEC enforcement action.","Investigation previously disclosed in Clover's periodic reports, including Q2 2024 10-Q filed Aug 8, 2024.","Company received notice under Securities Act Release No. 5310 guidelines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211118,"accession_number":"0001801170-24-000182","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Clover Health appoints former Molina Healthcare CFO Thomas L. Tran to Board and Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas L. Tran appointed Class II director and Audit Committee member; Board expanded from 8 to 9.","Tran brings 35+ yrs healthcare finance experience; was CFO of Molina Healthcare (2018-2021) and Upstream Care (2022-2023).","Tran receives pro-rated annual retainer and $200K RSU award for 2024 service under Clover's director compensation policy.","Tran entered standard indemnification agreement; no arrangements or family relationships with officers/directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211117,"accession_number":"0001801170-24-000158","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clover Health Q2 2024: first GAAP net income of $7.2M, raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 GAAP net income from continuing operations $7.2M vs. loss of $28.9M in Q2 2023; first positive quarter.","Total revenue $356.3M, up 11% YoY; Insurance revenue $349.9M, also up 11%.","Insurance MCR improved to 71.3% from 77.2% (590 bps improvement); Insurance BER improved to 76.1%.","Adjusted EBITDA $36.2M vs. $9.9M in Q2 2023.","FY2024 guidance raised: Insurance revenue $1.35B-$1.375B, Adjusted EBITDA $50M-$65M (from $10M-$30M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":703182000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211116,"accession_number":"0001801170-24-000152","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Court approves settlement of Clover Health derivative suits, dismisses cases with prejudice","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court approved settlement of four consolidated shareholder derivative actions against Clover and its directors.","Settlement provides for dismissal with prejudice, release of claims, and no admission of liability.","Court awarded $2.5M in plaintiffs' counsel fees and expenses, plus $3,000 service awards to seven plaintiffs.","Final judgment entered July 16, 2024; derivatives cases included in Tennessee, Delaware, and New York."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229653,"accession_number":"0001801170-24-000137","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Clover Health regains Nasdaq minimum bid price compliance after 10-day streak above $1.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received formal Nasdaq notice on June 26, 2024 that compliance with Listing Rule 5450(a)(1) is regained.","Required minimum $1.00 closing bid price for 10 consecutive trading days; achieved on June 25, 2024.","Earlier non-compliance notice was received April 2, 2024; Nasdaq has stated the matter is now closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229652,"accession_number":"0001801170-24-000135","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Clover Health amends bylaws to modify 'Acting in Concert' definition","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Board unanimously adopted Second Amended and Restated Bylaws on June 19, 2024, effective immediately.","Amendment revises the definition of 'Acting in Concert' contained in the bylaws.","No changes to fiscal year or articles of incorporation were made.","Full text of the amended bylaws filed as Exhibit 3.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229651,"accession_number":"0001801170-24-000124","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CMS upgrades Clover Health PPO Medicare Advantage Star rating to 3.5 for 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS recalculated Star rating from 3.0 to 3.5 Stars for 2025 payment year.","Over 95% of Medicare Advantage membership is in the affected PPO plans.","CEO says upgrade improves financial outlook and ability to scale Insurance business.","CFO states the upgrade allows opportunity to accelerate membership growth while maintaining profitability.","Previous 3.0 Star rating had been communicated as basis for 2025 planning."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229650,"accession_number":"0001801170-24-000122","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Clover Health stockholders elect directors, approve say-on-pay, ratify EY as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Chelsea Clinton, Carladenise Armbrister Edwards, and Vivek Garipalli as Class III directors with over 937M votes each.","Non-binding advisory vote to approve 2023 named executive officer compensation passed with ~950.6M for vs ~11M against.","Ratified Ernst & Young LLP as independent auditor for 2024 with ~1.1B votes for, ~5.3M against.","Broker non-votes of ~145.2M on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229649,"accession_number":"0001801170-24-000119","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Clover Health launches Counterpart Assistant for external payors, expanding SaaS platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clover Assistant rebranded as Counterpart Assistant; now generally available to external Medicare Advantage payors and providers.","New subsidiary Counterpart Health offers hybrid SaaS and shared-savings model with full capitation options.","Clinicians using Counterpart Assistant achieve over 1,000 bps lower Medical Cost Ratios.","First external clinician users are live; practices range from large health systems to small community practices.","CEO Andrew Toy says move expands lives managed by CA technology, aligning with mission to improve healthcare."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229648,"accession_number":"0001801170-24-000101","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Clover Health Q1 2024: first Adj. EBITDA profit $6.8M; guides to full-year profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Insurance revenue $341.7M (+7.8% YoY); total revenue $346.9M.","GAAP net loss from continuing ops improved to $23.2M from $79.7M loss in Q1 2023.","Adjusted EBITDA profit $6.8M versus loss $37.5M a year ago; Insurance MCR improved 870 bps to 77.9%.","Raised 2024 guidance: Insurance revenue $1.30B-$1.35B; Adj. EBITDA profitability $10M-$30M.","Board authorized $20M share repurchase over two years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":346922000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229647,"accession_number":"0001801170-24-000089","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Clover Health names Peter Kuipers as CFO; targets adjusted EBITDA profitability in 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter Kuipers appointed CFO effective after Q1 2024 10-Q filing; succeeds interim CFO Terrence Ronan.","Kuipers previously CFO at Omnicell (OMCL), helped grow revenue from $485M to $1.3B.","Employment terms: base salary $525k, target bonus 95% of base, $5M RSU grant (25% vest 1yr, remainder quarterly).","Company reiterates goal to achieve adjusted EBITDA profitability in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229646,"accession_number":"0001801170-24-000085","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Clover Health receives Nasdaq bid price deficiency notice; has until Sep 30, 2024 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 2, 2024 for CLOV closing below $1.00 for 30 consecutive business days.","Company has 180 days, until September 30, 2024, to regain compliance via a $1.00 close for 10 consecutive days.","Options to cure include a reverse stock split (subject to stockholder approval) or transfer to Nasdaq Capital Market.","If not compliant by Sep 30, may seek a second 180-day period by moving to Nasdaq Capital Market.","Failure to regain compliance could lead to delisting; appeal rights available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229645,"accession_number":"0001801170-24-000082","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Clover Health resolves derivative suits; $2.5M counsel fees, governance changes","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement requires no monetary payment to shareholders; $2.5M in fees to plaintiffs' counsel subject to court approval.","Company must implement corporate governance enhancements as part of settlement.","Court preliminarily approved settlement on March 5, 2024; final approval hearing set for July 11, 2024.","Derivative actions stemmed from Hindenburg Research allegations and 2021 de-SPAC merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248163,"accession_number":"0001801170-24-000063","cik":1801170,"company_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","ticker":"CLOV","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clover Health FY 2023 net loss improves to $213.4M; Insurance MCR drops to 81.2%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 net loss of $213.4M vs $339.6M in 2022; Insurance MCR improved to 81.2% from 91.8%.","Adjusted EBITDA loss narrowed to $44.7M in 2023 from $290.4M in 2022.","Q4 2023 revenue $510.3M; Insurance revenue grew 12% YoY to $303.1M.","FY 2024 guidance: Insurance MCR 79%-83%; up to $20M Adjusted EBITDA profitability at the high end.","Adjusted SG&A (non-GAAP) of $302.0M in FY 2023, down from $312.5M in FY 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2134655378.6498606,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}